ISSN: 1899-0967
Polish Journal of Radiology
Established by prof. Zygmunt Grudziński in 1926 Sun
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2022
vol. 87
 
Share:
Share:
more
 
 
Urogenital radiology
abstract:
Review paper

Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics

Yulian Mytsyk
1
,
Andriy Borzhiyevs’kyy
2
,
Yuriy Kobilnyk
2
,
A. V. Shulyak
3
,
Ihor Dutka
4
,
Oleksandr Borzhiyevs’kyy
2
,
Andrzej Górecki
5

1.
Department of Urology, Radiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2.
Department of Urology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
3.
Institute of Urology of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
4.
Department of Public Health, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
5.
Department of Radiology, Medical Care Centre, Jaroslaw, Poland
Pol J Radiol 2022; 87: e58-e62
Online publish date: 2022/01/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
Prostate cancer (PCa) is the second most common cancer in men. The urge to guide treatment tactics based on personal clinical risk factors has evolved in the era of human genome sequencing. To date, personalized approaches to managing PCa patients have not yet been developed. Radiogenomics is a relatively new term, used to refer to the study of genetic variation associated with imaging features of the tumour in order to improve the prognostication of the disease course.

Material and methods
The study is a review of recent knowledge regarding potential clinical applications of radio­genomics in personalized treatment of PCa.

Results
Recent investigations have proven that by combining data on individual genetic tumour features, and radiomic profiling (radiologic-molecular correlation), with traditional staging procedures in order to personalize treatment of PCa, an improved prognostication of PCa course can be performed, and overtreatment of indolent cancer can be avoided. It was found that a combination of multiparametric MRI and gene expression data allowed the detection of radiomic features of PCa, which correlated with a number of gene signatures associated with adverse outcomes. It was revealed that several molecular markers may drive tumour upstaging, allowed the distinction between the PCa stages, and correlated with aggressiveness-related radiomic features.

Conclusions
The radiogenomics of PCa is not a comprehensively investigated area of oncourology. The combination of genomics and radiomics as integrative parts of precision medicine in the future has the potential to become the foundation for a personalized approach to the management of PCa.

keywords:

prostate cancer, tumour markers, micro-RNA, personalized treatment, radiogenomics, multiparametric MRI




Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.